Related Experiment Video
Updated: Apr 29, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Bleeding complications during anticoagulant treatment in patients with cancer
Pieter W Kamphuisen1, Jan Beyer-Westendorf2
1Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract:
Patients with cancer have an increased risk of bleeding complications, of which some are fatal. This risk is influenced by chemotherapy, cancer type and stage, thrombocytopenia, renal function, and previous bleeding. Since many cancer patients receive anticoagulant treatment for prophylaxis or treatment of venous thromboembolism (VTE), bleeding complications are a challenge in clinical practice. This review article focuses on the overall bleeding risk of cancer patients and the risk of major and clinically relevant bleeding associated with anticoagulant treatment, such as vitamin K antagonists, LMWH and the direct oral anticoagulants. It also describes strategies for individual risk assessments.
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

